Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Jun
27
Fulfilling Our Ambition to Deliver an FDA-Approved Treatment for People Living with Generalized Myasthenia Gravis
Jun
27
UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis
Jun
14
How UCB Is Supporting the Mental Health of Patients and Caregivers
Jun
14
Recognizing Ethical Leadership at UCB
Jun
02
Prioritizing Mental Health as a Caregiver to a Child With Dravet Syndrome
Jun
01
Myasthenia Gravis Awareness Month is the Time to Understand More About the Lived Experiences of the Community
Apr
27
Voices on Value: Breaking Down the Value Chain: The Policies Impacting Patients
Apr
21
Earth Day 2023: Our Commitment to Sustainability in the Workplace
Apr
20
UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting
